FREQ Stock Price, Frequency Therapeutics Quote, Chart

Market Summary

USD0.160.00

Market Closed

0.00%

FREQ Stock Price

View Fullscreen

FREQ RSI Chart

FREQ Valuation

Market Cap

1.3M

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

0.1

EV/EBITDA

2.12

Price/Free Cashflow

-0.02

FREQ Price/Sales (Trailing)

FREQ Profitability

EBT Margin

-576.81%

Return on Equity

-43.71%

Return on Assets

-33.51%

Free Cashflow Yield

-5.9K%

FREQ Fundamentals

FREQ Revenue

Revenue (TTM)

14.1M

FREQ Earnings

Earnings (TTM)

-74.3M

Earnings Growth (Yr)

-556.43%

Earnings Growth (Qtr)

-178.31%

Breaking Down FREQ Revenue

Last 7 days

6.7%

Last 30 days

6.7%

Last 90 days

14.3%

Trailing 12 Months

-62%

How does FREQ drawdown profile look like?

FREQ Financial Health

Current Ratio

8.87

FREQ Investor Care

Buy Backs (1Y)

77.56%

Diluted EPS (TTM)

-266.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	34.4M	35.3M	24.0M	14.1M
2020	36.8M	44.7M	31.7M	37.0M
2019	0	0	0	28.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Frequency Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 21, 2023	lucchino david l.	sold	-1,528	0.5	-3,057	president and ceo
Aug 21, 2023	mitrano richard j.	sold	-125	0.53	-237	vp finance & operations
Aug 18, 2023	lucchino david l.	sold	-1,719	0.6	-2,865	president and ceo
Aug 18, 2023	mitrano richard j.	sold	-143	0.63	-227	vp finance & operations
Aug 17, 2023	lucchino david l.	sold	-1,721	0.63	-2,733	president and ceo
Aug 17, 2023	mitrano richard j.	sold	-142	0.62	-230	vp finance & operations
Aug 16, 2023	mitrano richard j.	sold	-156	0.67	-234	vp finance & operations
Aug 16, 2023	lucchino david l.	sold	-1,881	0.65	-2,895	president and ceo
Aug 15, 2023	mitrano richard j.	sold	-148	0.65	-228	vp finance & operations
Aug 15, 2023	lucchino david l.	sold	-1,761	0.67	-2,629	president and ceo

Which funds bought or sold FREQ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-370	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-630,657	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-78,470	-	-%
Feb 20, 2024	EVENTIDE ASSET MANAGEMENT, LLC	sold off	-100	-10,000,000	-	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-4,391	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	sold off	-100	-444,000	-	-%
Feb 14, 2024	TWO SIGMA ADVISERS, LP	sold off	-100	-3,774	-	-%
Feb 14, 2024	Cresset Asset Management, LLC	sold off	-100	-13,875	-	-%

Are Funds Buying or Selling FREQ?

Are funds buying FREQ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FREQ

No. of Funds

Unveiling Frequency Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cormorant asset management, lp	3.90%	312,052	SC 13G/A
Feb 14, 2024	eventide asset management, llc	6.83%	546,325	SC 13G
Feb 14, 2024	citadel advisors llc	6.6%	6	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Nov 17, 2023	platanus investment llc	6.8%	540,165	SC 13G
Nov 17, 2023	new enterprise associates 17, l.p.	13.4%	1,072,936	SC 13D
Nov 16, 2023	cormorant asset management, lp	5.77%	462,052	SC 13G
Nov 13, 2023	atlas venture fund xi, l.p.	11.8%	942,075	SC 13D
Nov 13, 2023	citadel advisors llc	6.8%	6	SC 13G
Nov 13, 2023	artal international s.c.a.	5.2%	418,605	SC 13G

Recent SEC filings of Frequency Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 22, 2024	424B3	Prospectus Filed
Apr 19, 2024	PRE 14A	PRE 14A
Apr 18, 2024	8-K	Current Report
Apr 18, 2024	424B3	Prospectus Filed
Mar 28, 2024	424B3	Prospectus Filed
Mar 27, 2024	EFFECT	EFFECT
Mar 26, 2024	S-8	Employee Benefits Plan
Mar 26, 2024	POS AM	POS AM
Mar 26, 2024	8-K	Current Report

Peers (Alternatives to Frequency Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.9B	6.8B	-0.89%	-25.81%	-8.47	5.83	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	5.17%	-8.18%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-8.90%	-30.41%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.4B	-	-15.28%	57.81%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-11.84%	-2.48%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-11.98%	-22.42%	-10	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.71	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.94%	-8.31%	24.94	4.47	85.90%	-14.05%
NVAX	572.4M	983.7M	-12.98%	-52.88%	-1.05	0.58	-50.36%	17.16%
CRBP	395.6M	881.7K	7.90%	326.47%	-8.87	466.16	-77.61%	-5.33%
INO	233.7M	4.9M	-13.94%	-3.10%	-1.73	48.02	-54.97%	51.71%
IBIO	6.2M	2.1M	63.30%	36.92%	-0.23	2.14	-13.45%	66.37%

Frequency Therapeutics Inc News

Latest updates

Frequency Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	-	-	-	9,417,000	4,651,000	9,950,000	11,247,000	8,523,000	7,264,000	4,709,000	24,238,000
Operating Expenses	-265.1%	-41,246,000	24,990,000	26,900,000	24,850,000	20,227,000	16,665,000	14,723,000	12,919,000	11,197,000	25,490,000
S&GA Expenses	-281.0%	-16,882,000	9,328,000	9,499,000	9,744,000	8,399,000	6,512,000	5,959,000	6,249,000	5,001,000	4,269,000
R&D Expenses	-255.6%	-24,364,000	15,662,000	17,401,000	15,106,000	11,828,000	10,153,000	8,764,000	6,670,000	6,196,000	5,221,000
EBITDA Margin	52.9%	-1.39	-2.96	-1.46	-1.18	-0.68	-	-	-	-	-
Interest Expenses	0%	182,000	182,000	182,000	218,000	-	-	-	-	-	-
Income Taxes	-466.7%	-11,000	3,000	10,000	-	-25,000	15,000	7,000	38,000	-	-
Earnings Before Taxes	263.9%	41,216,000	-25,152,000	-17,646,000	-20,375,000	-10,257,000	-5,326,000	-6,018,000	-4,875,000	-5,493,000	-575,000
EBT Margin	48.9%	-1.56	-3.06	-1.52	-1.22	-0.72	-	-	-	-	-
Net Income	263.9%	41,227,000	-25,155,000	-17,656,000	-20,375,000	-10,232,000	-5,341,000	-6,025,000	-4,913,000	-5,493,000	-575,000
Net Income Margin	48.9%	-1.56	-3.06	-1.52	-1.22	-0.72	-	-	-	-	-
Free Cashflow	264.2%	25,178,000	-15,334,000	-19,673,000	-26,017,000	-19,251,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	131.3%	222	96.00	79.00	102	74.00	136	150	165	128	202	220	242	265	234	205	216	223	171	45.00
Current Assets	251.5%	173	49.00	48.00	69.00	57.00	101	113	120	120	150	172	200	225	227	198	210	221	167	43.00
Cash Equivalents	260.3%	166	46.00	40.00	41.00	36.00	48.00	42.00	50.00	83.00	112	135	169	40.00	224	195	203	200	142	42.00
Net PPE	21.5%	16.00	13.00	1.00	2.00	10.00	3.00	4.00	5.00	6.00	6.00	7.00	7.00	7.00	3.00	3.00	2.00	2.00	2.00	2.00
Liabilities	30.1%	52.00	40.00	34.00	48.00	9.00	54.00	54.00	52.00	6.00	55.00	54.00	64.00	72.00	35.00	43.00	51.00	56.00	79.00	-
Current Liabilities	104.2%	19.00	10.00	8.00	22.00	9.00	20.00	17.00	12.00	5.00	10.00	9.00	19.00	27.00	33.00	41.00	44.00	53.00	72.00	4.00
LT Debt, Current	-	-	-	-	12.00	10.00	8.00	6.00	3.00	1.00	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	362.5%	170	37.00	45.00	53.00	69.00	82.00	96.00	113	131	147	166	177	192	200	162	165	167	-	-
Retained Earnings	-16.1%	-183	-157	-292	-281	-101	-244	-224	-203	-43.80	-158	-133	-115	-95.40	-85.17	-79.83	-73.80	-68.89	-63.35	-49.09
Additional Paid-In Capital	8078.6%	353	4.00	337	334	3.00	327	321	316	2.00	306	299	293	288	285	241	239	236	4.00	1.00
Shares Outstanding	33.6%	8.00	6.00	36.00	36.00	-	5.00	35.00	35.00	5.00	35.00	34.00	34.00	-	-	-	-	-	-	-
Float	-	-	-	12.00	-	-	-	47.00	-	-	-	306	-	-	-	626	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	10.6%	-21,107	-23,620	-8,424	-14,132	-15,033	-7,791	-13,478	-17,343	26,077	-15,023	-17,674	-25,474	-14,833	-10,730	-10,262	-9,363	-29,742	74,580	-4,472	-6,150	-
Share Based Compensation	100.0%	-	-5,174	2,897	3,431	235	-8,925	4,564	5,266	-15,779	5,886	6,089	4,611	2,765	2,643	2,411	2,164	1,153	925	1,482	49.00	-
Cashflow From Investing	86.1%	-1,655	-11,891	19,211	5,499	3,089	14,612	6,021	-12,662	11,978	-8,414	-16,856	-26,209	-4,435	-1,017	2,166	13,688	5,429	4,638	7,013	-35,341	-
Cashflow From Financing	152.3%	144,588	57,308	-11,667	-2,468	14.00	-196	-	200	114,696	349	328	572	15,383	40,605	391	309	82,198	59,387	88.00	342	-

FREQ Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 57,250	$ 42,201
General and administrative	27,284	16,797
Total operating expenses	84,534	58,998
Loss from operations	(84,534)	(58,998)
Other income:
Other income, net	3,389	976
Total other income, net	3,389	976
Loss before provision for income taxes	(81,145)	(58,022)
Provision for income taxes	27	10
Net loss	(81,172)	(58,032)
Other comprehensive income
Unrealized gain on available-for-sale investments	0	2
Comprehensive loss	$ (81,172)	$ (58,030)
Net loss per share, basic	$ (53.08)	$ (227.42)
Net loss per share, diluted	$ (53.08)	$ (227.42)
Weighted-average shares used in computing net loss per share, basic	1,529,321	255,175
Weighted-average shares used in computing net loss per share, diluted	1,529,321	255,175

FREQ Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 166,150	$ 36,333
Short-term investments	0	18,915
Restricted cash	3,563	603
Prepaid expenses and other current assets	3,015	1,232
Total current assets	172,728	57,083
Property and equipment, net	15,665	9,866
Operating lease right-of-use assets	27,150	2,024
Restricted Cash, net of current portion	3,406	4,541
Other non-current assets	2,714	228
Total assets	221,663	73,742
Current Liabilities
Accounts payable	7,280	2,605
Accrued expenses and other current liabilities	10,212	3,175
Operating lease liabilities, current portion	1,991	2,921
Total current liabilities	19,483	8,701
Operating lease liabilities, net of current portion	31,216	209
Other non-current liabilities	1,053	0
Total liabilities	51,752	8,910
Commitments and contingencies (Note 13)
Stockholders' equity (deficit)
Preferred stock, $0.001 par value; 10,000,000 shares and no shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 200,000,000 and 5,755,759 shares authorized at December 31, 2023 and 2022; 8,016,516 and 271,371 shares issued at December 31, 2023 and 2022, respectively; 8,016,516 and 268,468 shares outstanding at December 31, 2023 and 2022	8	0
Additional paid-in capital	352,908	2,807
Accumulated other comprehensive loss	0	(5)
Accumulated deficit	(183,005)	(101,833)
Total stockholders' equity (deficit)	169,911	(99,031)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	221,663	73,742
Series Seed Convertible Preferred Stock [Member]
Current Liabilities
Temporary equity, convertible preferred stock	0	15,924
Series A Preferred Stock [Member]
Current Liabilities
Temporary equity, convertible preferred stock	0	77,736
Series B-1 Preferred Stock [Member]
Current Liabilities
Temporary equity, convertible preferred stock	0	57,703
Series B-2 Preferred Stock [Member]
Current Liabilities
Temporary equity, convertible preferred stock	$ 0	$ 12,500

About Frequency Therapeutics Inc

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

CEO	Mr. David L. Lucchino
WEBSITE	frequencytx.com
INDUSTRY	Biotechnology
EMPLOYEES	46

Frequency Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Frequency Therapeutics Inc? What does FREQ stand for in stocks?

FREQ is the stock ticker symbol of Frequency Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Frequency Therapeutics Inc (FREQ)?

As of Fri Apr 19 2024, market cap of Frequency Therapeutics Inc is 1.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FREQ stock?

You can check FREQ's fair value in chart for subscribers.

What is the fair value of FREQ stock?

You can check FREQ's fair value in chart for subscribers. The fair value of Frequency Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Frequency Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FREQ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Frequency Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FREQ is over valued or under valued. Whether Frequency Therapeutics Inc is cheap or expensive depends on the assumptions which impact Frequency Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FREQ.

What is Frequency Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, FREQ's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 0.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FREQ PE ratio will change depending on the future growth rate expectations of investors.